The Nov. 30 release of data from a transcatheter aortic valve replacement (TAVR) registry provided clinicians, patients and payers with robust, real world information on a procedure that’s becoming more popular.

An actuarial analysis found that patients who receive sacubitril/valsartan may have an increased life expectancy and reduced risk of death from cardiovascular causes or hospitalization for heart failure compared with patients who take enalapril.

The American College of Cardiology, Geisinger Health System and xG Health Solutions announced a new joint initiative to enhance the processes and outcomes of clinical care for patients with heart failure.

Patients who underwent transcatheter aortic valve replacement (TAVR) in the U.S. from 2012 to 2014 tended to be at least 80 years old and have multiple comorbidities, a high predicted risk of mortality and a poor self-reported health status, according to a registry analysis.

The FDA approved the AngioJet ZelanteDVT thrombectomy catheter on Nov. 30 to treat patients with deep vein thrombosis. The catheter also received a CE Mark on the same day for approval in Europe.

Hear what’s new from Meril's vice president, Sanjeev Bhatt, on tapered drug eluting stents, bioabsorbable scaffolds, dilatation catheters and TAVR.

Although guidelines recommend against the use of pulmonary artery catheters for routine management of heart failure, physicians have significantly increased their use of pulmonary artery catheters in recent years, according to an analysis of heart failure hospitalizations.

Boston Scientific recalled its RotaWire Elite Guidewires and wireClip Torquer Guidewires after receiving three reports of the wires cracking and separating from the Rotablator Rotational Atherectomy System.